Parataxis on Friday announced that it has invested $18.5 million to acquire a controlling interest in Korean firm Bridge Biotherapeutics, Inc. The acquisition will result in the formation of a Public Bitcoin Treasury platform.
As a result of the transaction, a Bitcoin-native treasury platform anchored by institutional investors with substantial expertise in digital asset investments would be established in South Korean public markets.
Edward Chin to Join Parataxis Korea Board Following Strategic Acquisition
Founder and CEO of Parataxis Holdings and Co-Founder and CEO of Parataxis Capital, Edward Chin, will join the company’s board of directors as part of the transaction.
In addition to joining the board of directors, Andrew Kim, a partner at Parataxis Capital, will take on the position of CEO. James Jungkue Lee, a co-founder of Bridge Bio, will remain on the board of directors and continue to oversee the company’s primary biotech business.
Commenting on the purchase, Andrew Kim said “Inspired by the growing interest in BTC treasury strategies seen in companies like Strategy in the US and Metaplanet in Japan, we believe institutional interest in this space is increasing globally. We see South Korea as an important market in the evolution of BTC adoption.”
“Our intent is to support institutional access to BTC exposure while emphasizing sound corporate governance and disciplined capital management,” added Andrew Kim.
Also Read: Bank Of Korea’s Governor Lee Chang‑yong Says, Must Consider ‘FX Stability’ On Won‑Based Stablecoins
Parataxis Holdings Closes New Fund, Plans Additional Crypto-Focused Vehicles
In addition to getting ready for the potential purchase, Parataxis Holdings is closing a different fund with a comparable investment approach and preparing to introduce more fund vehicles.
This action highlights the company’s overarching goals to increase the impact of its digital assets and cryptocurrency, especially through institutional channels.
Following an August shareholder meeting, the business intends to release more information regarding the transaction.
Deloitte is Parataxis Korea Fund I LLC’s financial advisor in the transaction, and Shin & Kim LLC is its legal advisor.
It appears from these events that Parataxis is establishing itself as a major participant in the developing crypto-financial infrastructure of the Korean market and creating the foundation for a more extensive strategic strategy.
Also Read: Haru Invest CEO Lee Hyung‑soo Cleared Of More Than $1B Crypto Fraud By South Korean Court
Parataxis Holdings Drives Institutional Crypto Integration in Asian Markets
The significance of Parataxis Holdings’ strategic moves lies in its bold push to integrate institutional finance with digital assets, especially in Asia.
By acquiring Bridge Biotherapeutics and rebranding it as Parataxis Korea, the firm is setting a precedent—building what may become the first institutionally backed Bitcoin treasury platform in the South Korean public markets.
This mirrors strategies seen in the U.S. and Japan (like MicroStrategy or Metaplanet), but localized for Asia’s fast-evolving crypto landscape.
Simultaneously launching additional fund vehicles and closing a second fund with the same crypto-centric strategy signals growing institutional confidence in digital assets as long-term stores of value.
With major advisors like Deloitte and Shin & Kim on board, Parataxis is showing it intends to operate with full regulatory and financial rigor—something crucial for institutional adoption.
If successful, this could spark a broader trend of publicly listed Asian firms embracing crypto treasury strategies.
Also Read: South Korea’s President Lee Pushes Bill Allowing Local Companies To Issue Stablecoins